Mizuho Securities Cuts Price Target on CareDx (CDNA) to $8 Following Allenex Acquisition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Piper Jaffray Remains Bullish on CareDx (CDNA) Following Presentation of AlloSure Performance
June 14, 2016 9:07 AM EDTPiper Jaffray maintained an Overweight rating and $6.00 price target on CareDx, Inc (NASDAQ: CDNA) following the company's presentation of its DART clinical trial. Piper Jaffray would describe DART's first look data as solid with AlloSure a significantly better predictor of kidney health than creatinine.
Analyst William Quirk... More
Unusual 11 Mid-Day Movers 6/13: (EBIO) (LNKD) (PWE) Higher; (MRNS) (GBR) (ARGS) Lower
June 13, 2016 1:01 PM EDTMarinus Pharmaceuticals, Inc. (Nasdaq: MRNS) 69.6% LOWER; announced top-line results from its Phase 3 clinical trial in adults with drug-resistant focal onset seizures. In this trial, ganaxolone did not meet the primary endpoint of demonstrating a statistically significant difference from placebo. Consistent with previously conducted studies, ganaxolone was generally safe and well tolerated. Marinus plans to discontinue its program in adult focal onset seizures and focus its efforts on advancing ganaxolone in status epilepticus and pediatric orphan indications.
